NDA 209376 · Am Regent
Multrys
Cupric Sulfate, Manganese Sulfate, Selenious Acid, Zinc Sulfate · Intravenous
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 2, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
14
10 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2024.
Multrys is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Multrys is a combination of trace elements (zinc sulfate, cupric sulfate, manganese sulfate, and selenious acid) indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )
Mechanism: Zinc Zinc functions as a cofactor of various enzymes including DNA polymerases, RNA polymerases, alcohol dehydrogenase, and alkaline phosphatases. Zinc is a coordinator of protein structural folding that interacts with a variety of proteins, lipids, and nucleic acids. In addition, zinc is a catalyst of essential biochemical reactions, including activation of substrates of carbonic anhydrase in erythrocyte. Copper Copper is a cofactor for many metalloenzymes acting as an oxidase to achieve reduction of molecular oxygen. Examples of copper metalloenzymes include but are not limited to lysyl...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- MULTRYS · CUPRIC SULFATE EQ 60MCG COPPER/ML; MANGANESE SULFATE EQ 3MCG BASE/ML; SELENIOUS ACID EQ 6MCG SELENIUM/ML; ZINC SULFATE EQ 1000MCG BASE/ML (1ML) · SOLUTION, INTRAVENOUS · Prescription
- TRALEMENT · CUPRIC SULFATE EQ 0.3MG COPPER/ML; MANGANESE SULFATE EQ 55MCG BASE/ML; SELENIOUS ACID EQ 60MCG SELENIUM/ML; ZINC SULFATE EQ 3MG BASE/ML (1ML) · SOLUTION, INTRAVENOUS · Prescription
- TRALEMENT · CUPRIC SULFATE EQ 0.3MG COPPER/ML; MANGANESE SULFATE EQ 55MCG BASE/ML; SELENIOUS ACID EQ 60MCG SELENIUM/ML; ZINC SULFATE EQ 3MG BASE/ML (5ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cupric" as an intervention, any sponsor and status, largest first.
- The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and InsufficientPivotal-lookingStatus unknown
Universitas IndonesiaAcademic, hospital or other
NCT06054919 · 52 participants · Start Apr 1, 2021 · Primary completion Nov 30, 2023
Drug: Cholecalciferol · For: Vitamin D Deficiency
Sites: Jakarta Pusat, Indonesia
American Regent, Inc.Industry
NCT05677126 · 0 participants · Start Aug 2024 · Primary completion Aug 2024
Drug: Tralement; Fixed-dose trace element combination product of zinc, copper, and selenious acid · For: Manganese Safety in Pediatric Patients
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia4
- product label confusion3
- anaemia2
- diarrhoea2
- fall2
- hospitalisation2
- infection2
- muscular weakness2
- pain2
- physical product label issue2
- product dose omission issue2
- vomiting2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 7 |
Recalls
2 FDA enforcement reports for this application.
Jul 24, 2026 · Class II · Ongoing
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Jul 24, 2026 · Class II · Ongoing
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
· Arch Ophthalmol 2001 · Clinical Trial, Comparative Study
- Copper toxicity to earthworms: A comprehensive review and meta-analysis.
Pelosi C, Gavinelli F, Petit-Dit-Grezeriat L, et al. · Chemosphere 2024 · Meta-Analysis, Review
- Zinc supplementation inhibits complement activation in age-related macular degeneration.
Smailhodzic D, van Asten F, Blom AM, et al. · PLoS One 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Prediction of antioxidant capacity, age, and sex on sleep impairment in patients with amyotrophic lateral sclerosis.
Sancho-Cantus D, Sanchis ES, Casani-Cubel J, et al. · Sci Rep 2025 · Randomized Controlled Trial
- Assessment of intramuscular emulsified disulfiram in alcoholics by estimation of urinary diethylamine.
Carey-Smith KA, Joll TA, Nyoni VS, et al. · J Stud Alcohol 1988 · Clinical Trial, Controlled Clinical Trial
- Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification.
Ishikawa T, Suzukawa M, Ito T, et al. · Am J Clin Nutr 1997 · Clinical Trial, Randomized Controlled Trial
Sponsor: Am Regent · Also marketed as Tralement
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.